Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 184
- Registration Number
- NCT06386302
- Locations
- 🇨🇳
Blood Hospital, Tianjin, Tianjin, China
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06384261
- Locations
- 🇺🇸
The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇨🇦Tom Baker Cancer Center-Alberta Health Services - University of Calgary, Calgary, Alberta, Canada
🇨🇦Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta, Edmonton, Alberta, Canada
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06326697
- Locations
- 🇸🇦
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 147
- Registration Number
- NCT06317649
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06285890
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Cladribine Venetoclax in Monocytic AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 40
- Registration Number
- NCT06232655
- Locations
- 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 90
- Registration Number
- NCT06196203
- Locations
- 🇺🇸
Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06177067
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Antonio M Jimenez Jimenez
- Target Recruit Count
- 25
- Registration Number
- NCT06158100
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.